At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,001 enrolled
Drug / intervention
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2% Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients With Open-Angle Glaucoma and/or Ocular Hypertension
In Brief
A Phase 3 clinical trial evaluating Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, and 1 other intervention for Open-Angle Glaucoma and Ocular Hypertension. Completed, enrolled 1,001 participants.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of a fixed combination of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma and/or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedFeb 16, 2011
Enrollment StartFeb 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.4 years ago
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspensiondrug
Brinzolamide ophthalmic suspension, 1%drug
Brimonidine tartrate ophthalmic solution, 0.2%drug